HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with...